According to filings with the U.S. Securities and Exchange Commission, Biostem Technologies is raising $5,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Jason Matsuzewski played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Biostem Technologies
BioStem Technologies, Inc. is a pre-clinical-stage biotechnology company focused on harnessing elements of Perinatal Tissue and the body s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Our proprietary approach, called Local MicroEnvironment Activation, or LMA, uses combinations of Small Molecules, Cytokines, and Growth Factors (SMCGF) to activate the microenvironment within the body to create communication for repair in the tissue. At BioStem Technologies, quality is top priority to us because we value patient safety above all else. In our AATB accredited, FDA-registered, cGMP compliant lab, we strive to provide products and services which not only meet but exceed, Current Good Tissue Practice requirements. By developing novel approaches to industry-changing processes, we focus on better than status quo.

To learn more about Biostem Technologies, visit http://www.biostemtechnologies.com/

Contact:
Jason Matsuzewski, Chief Executive Officer
954-380-8342
https://www.linkedin.com/in/jason-matuszewski-034163b4/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.